Search results

Learn how to use the Black-Scholes Model to value stock options in a private company, including the BSM formula, key assumptions, and limitations.

Learn everything you need to know about 409A valuations including what they are, when you need a valuation, valuation methodologies, and the full process.

In Q2 2024, the venture ecosystem showed modest signs of improvement.

After holding steady in 2023, the median seed valuation has now jumped in two straight quarters, a sign that VCs are feeling optimistic about early-stage startups.

Over the past five years, dilution levels have declined at every stage of startup life. This can have compounding effects for the makeup of company cap tables.

Initial data from Q2 2024 shows modest increases in median valuation and round size across much of the U.S. venture ecosystem.

In a tight market for primary venture fundraising, a historically high number of startups are turning to bridge rounds.

Learn the differences between pre-money and post-money valuations for private companies and how to calculate preferred share price when pitching investors during a priced round.

Health and biotech VC fundraising surged in the aftermath of the COVID-19 pandemic and has stood strong against market headwinds.

After two-plus years of steady declines, the Series C market may be bouncing back.

At Series D and later, VC deal activity slowed down in Q1 2024. There are reasons for the decline on both sides of the negotiating table.